FDA Terminates Class II Recall for Matthew 7:25 Inc dba Thrive Pharmacy's Subpotent Buprenorphine Troches
Matthew 7:25 Inc dba Thrive Pharmacy faced an FDA Class II recall for subpotent Buprenorphine Black Cherry 2 mg Troches, lot 191217A, distributed in Florida. This voluntary, firm-initiated action, terminated in June 2023, highlights critical quality control failures. Procurement and regulatory teams must enhance due diligence for compounded products to mitigate efficacy and safety risks.
FDA Initiates Class II Recall for Subpotent Buprenorphine Troches from Thrive Pharmacy
Matthew 7:25 Inc dba Thrive Pharmacy, operating from Jacksonville, Florida, initiated a voluntary Class II recall (recall number D-1054-2020) for its Buprenorphine Black Cherry 2 mg Troche. This action, initiated on March 10, 2020, and officially terminated by the FDA on June 2, 2023, addressed a critical quality deviation: the product was found to be subpotent. The specific lot affected was 191217A, with an expiration date of June 14, 2020, involving a quantity of 89 troches distributed exclusively within Florida. For procurement directors and supply chain VPs, this event underscores the critical importance of robust quality control systems, even within smaller-scale compounding pharmacies. It signals a need for rigorous qualification processes for all suppliers, regardless of their size or geographic reach, to ensure product integrity and patient safety. Regulatory affairs heads must monitor such recalls closely, as they reflect ongoing FDA scrutiny on drug quality across the industry, demanding proactive risk mitigation strategies.
Regulatory Findings: Subpotency Risks and Patient Safety Implications
The core issue identified in this recall was the subpotency of the Buprenorphine Black Cherry 2 mg Troche. A subpotent drug contains less active ingredient than specified, which can lead to reduced therapeutic efficacy and potentially inadequate treatment for patients. Given that Buprenorphine is commonly used for opioid dependence treatment or pain management, a subpotent formulation could have serious consequences, including treatment failure or withdrawal symptoms. The FDA classified this as a Class II recall, indicating that the product "may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote." For business development executives, this highlights the significant reputational and financial risks associated with quality failures. A subpotent drug can lead to treatment failures, patient harm, and ultimately, erosion of trust in the supplier. Supply chain VPs must recognize that even a limited recall of 89 troches can trigger substantial regulatory oversight and necessitate costly remediation efforts, impacting operational continuity and market access.
Commercial Impact and Enhanced Due Diligence for Compounding Pharmacies
While the recall (D-1054-2020) was firm-initiated and has been terminated, the underlying cause—a subpotent drug—demands heightened attention from industry stakeholders. Procurement teams sourcing active pharmaceutical ingredients (APIs) or finished drug products from compounding pharmacies, such as Matthew 7:25 Inc dba Thrive Pharmacy in Jacksonville, FL, must intensify their due diligence. This incident demonstrates that quality deviations can occur even in localized distribution networks, impacting patient outcomes and regulatory standing. Regulatory affairs professionals should advise on establishing comprehensive audit programs, including on-site inspections and analytical testing verification, to ensure that suppliers consistently meet potency specifications and adhere to Good Manufacturing Practices (GMP). This proactive approach is essential to safeguard product quality, prevent future recalls that disrupt supply chains, and protect brand reputation in a highly scrutinized pharmaceutical market. The cost of preventing such incidents far outweighs the expense of managing a recall and its aftermath.